Moleculin Doses First Subjects In Phase 2 Portion Of Clinical Trial Evaluating Annamycin In Combination With Cytarabine For The Treatment Of Acute Myeloid Leukemia
Portfolio Pulse from Benzinga Newsdesk
Moleculin Biotech has begun dosing subjects in the Phase 2 portion of its clinical trial evaluating Annamycin in combination with Cytarabine for the treatment of Acute Myeloid Leukemia (AML). The Phase 1B portion of the study demonstrated a preliminary CR/CRi rate of 33%. Annamycin has received Fast Track Status and Orphan Drug Designation from the FDA for the treatment of AML.
October 02, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moleculin Biotech's initiation of Phase 2 clinical trials for Annamycin could potentially boost investor confidence, given the promising results from Phase 1B and the FDA's Fast Track Status and Orphan Drug Designation for the drug.
The initiation of Phase 2 trials indicates progress in Moleculin's drug development, which could positively impact investor sentiment. The promising results from Phase 1B and the FDA's Fast Track Status and Orphan Drug Designation for Annamycin further enhance the drug's prospects, potentially leading to a positive impact on Moleculin's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100